Bridging a Patient With Acute Liver Failure to Liver Transplantation by the AMC-Bioartificial Liver
Abstract:Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient’s blood or blood cells up to 12 months after treatment.
Document Type: Research Article
Affiliations: 1: *Surgical Laboratory (IWO-1), Department of Surgery, Academic Medical Center, University of Amsterdam, The Netherlands 2: ‡Liver Transplantation Unit, Department of Surgery, Cardarelli Hospital, Centro di Biotecnologie A. O. Cardarelli, Naples, Italy 3: §Centro di Biotecnologie A. O. Cardarelli, Naples, Italy 4: ¶Virology Laboratory, D. Cotugno Hospital, Naples, Italy 5: #VI Division of Infectious Diseases, D. Cotugno Hospital, Naples, Italy 6: †Surgical Laboratory (IWO-1), Department of Hepatology, Academic Medical Center, University of Amsterdam, The Netherlands
Publication date: 2002-12-01
- Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.